Jeffrey Schlom

49.8k total citations · 6 hit papers
783 papers, 38.9k citations indexed

About

Jeffrey Schlom is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Jeffrey Schlom has authored 783 papers receiving a total of 38.9k indexed citations (citations by other indexed papers that have themselves been cited), including 423 papers in Immunology, 355 papers in Oncology and 251 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Jeffrey Schlom's work include Immunotherapy and Immune Responses (334 papers), Monoclonal and Polyclonal Antibodies Research (217 papers) and Cancer Immunotherapy and Biomarkers (213 papers). Jeffrey Schlom is often cited by papers focused on Immunotherapy and Immune Responses (334 papers), Monoclonal and Polyclonal Antibodies Research (217 papers) and Cancer Immunotherapy and Biomarkers (213 papers). Jeffrey Schlom collaborates with scholars based in United States, Italy and Germany. Jeffrey Schlom's co-authors include James W. Hodge, James L. Gulley, David Colcher, Patricia Horan Hand, John W. Greiner, Claudia Palena, Philip M. Arlen, Caroline Jochéms, S. Spiegelman and Ann D. Thor and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Jeffrey Schlom

772 papers receiving 37.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

2006 1.3k citations James W. Hodge, Jeffrey Schlom et al. profile →
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

2010 727 citations Jeffrey Schlom, William L. Dahut et al. profile →
Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

2005 712 citations Jeffrey Schlom et al. profile →
Differential Reactivity of a Novel Monoclonal Antibody (DF3) with Human Malignant versus Benign Breast Tumors

1984 480 citations Jeffrey Schlom et al. profile →
A spectrum of monoclonal antibodies reactive with human mammary tumor cells.

1981 461 citations Jeffrey Schlom et al. profile →
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

2018 327 citations Julius Strauss, Christopher R. Heery et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Jeffrey Schlom

Since Specialization

Citations

This map shows the geographic impact of Jeffrey Schlom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Schlom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Schlom more than expected).

Fields of papers citing papers by Jeffrey Schlom

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Schlom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Schlom. The network helps show where Jeffrey Schlom may publish in the future.

Co-authorship network of co-authors of Jeffrey Schlom

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Schlom. A scholar is included among the top collaborators of Jeffrey Schlom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Schlom. Jeffrey Schlom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer 2025 ·Cancer Immunology Research ·Maria Gracia-Hernandez, María del Mar Maldonado, Jeffrey Schlom, Duane H. Hamilton	0
2	Therapy of Established Tumors with Rationally Designed Multiple Agents Targeting Diverse Immune–Tumor Interactions: Engage, Expand, Enable 2020 ·Cancer Immunology Research ·Kellsye P. Fabian, Anthony S. Malamas, Michelle R. Padget, Kristen Solocinski, Benjamin Wolfson, Rika Fujii, Houssein Abdul Sater, Jeffrey Schlom, James W. Hodge	11
3	Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy 2019 ·Clinical Cancer Research ·Kristin C. Hicks, Karin M. Knudson, Karin L. Lee, Duane H. Hamilton, James W. Hodge, William D. Figg, Peter Ordentlich, Frank R. Jones, Shahrooz Rabizadeh, Patrick Soon‐Shiong, Jeffrey Schlom, Sofia R. Gameiro	37
4	A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules 2019 ·Clinical Cancer Research ·Margaret E. Gatti‐Mays, Julius Strauss, Renee N. Donahue, Claudia Palena, Jaydira Del Rivero, Jason M. Redman, Ravi A. Madan, Jennifer L. Marté, Lisa M. Cordes, Elizabeth Lamping, (unknown), (unknown), Eva Wagner, (unknown), Christopher R. Heery, Jeffrey Schlom, James L. Gulley	45
5	Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models 2019 ·Clinical Cancer Research ·Sarah Greene, Yvette Robbins, Wojciech K. Mydlarz, (unknown), Nicole C. Schmitt, Jay Friedman, Lucas A. Horn, Claudia Palena, Jeffrey Schlom, Dean Y. Maeda, John A. Zebala, Paúl E. Clavijo, Clint Allen	217
6	Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy 2019 ·Cancer Immunology Research ·Karin L. Lee, Stephen C. Benz, Kristin C. Hicks, Andrew Nguyen, Sofia R. Gameiro, Claudia Palena, (unknown), Zhen Su, Peter Ordentlich, Lars Rohlin, (unknown), Shahrooz Rabizadeh, Patrick Soon‐Shiong, Kayvan Niazi, Jeffrey Schlom, Duane H. Hamilton	20
7	First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors 2018 ·Clinical Cancer Research ·Julius Strauss, Christopher R. Heery, Joseph W. Kim, Caroline Jochéms, Renee N. Donahue, (unknown), Sheri McMahon, Elizabeth Lamping, Jennifer L. Marté, Ravi A. Madan, Marijo Bilušić, Matthew R. Silver, (unknown), Jeffrey Schlom, James L. Gulley	116
8	Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors breakdown → 2018 ·Clinical Cancer Research ·Julius Strauss, Christopher R. Heery, Jeffrey Schlom, Ravi A. Madan, Liang Cao, Zhigang Kang, Elizabeth Lamping, Jennifer L. Marté, Renee N. Donahue, Italia Grenga, Lisa M. Cordes, Olaf Christensen, Lisa Mahnke, Christoph Helwig, James L. Gulley	327
9	Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types 2016 ·Lauren M. Lepone, Renee N. Donahue, Italia Grenga, Simon Metenou, Jacob Richards, Christopher R. Heery, Ravi A. Madan, James L. Gulley, Jeffrey Schlom	3
10	Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells 2015 ·Cancer Immunology Research ·Benjamin Boyerinas, Caroline Jochéms, Massimo Fantini, Christopher R. Heery, James L. Gulley, Kwong Y. Tsang, Jeffrey Schlom	360
11	Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury 2015 ·Cancer Immunology Research ·Christopher R. Heery, (unknown), Myrna Rauckhorst, Jennifer L. Marté, Renee N. Donahue, Italia Grenga, Timothy C. Rodell, William L. Dahut, Philip M. Arlen, Ravi A. Madan, Jeffrey Schlom, James L. Gulley	104
12	Vaccine-Mediated Immunotherapy Directed against a Transcription Factor Driving the Metastatic Process 2014 ·Cancer Research ·Andressa Ardiani, Sofia R. Gameiro, Claudia Palena, Duane H. Hamilton, Anna Kwilas, Thomas H. King, Jeffrey Schlom, James W. Hodge	29
13	Serum Antibodies to Blood Group A Predict Survival on PROSTVAC-VF 2013 ·Clinical Cancer Research ·(unknown), James L. Gulley, Oyindasola Oyelaran, James W. Hodge, Jeffrey Schlom, Jeffrey C. Gildersleeve	36
14	Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer 2013 ·Cancer Immunology Research ·James L. Gulley, Ravi A. Madan, Kwong Y. Tsang, Caroline Jochéms, Jennifer L. Marté, Benedetto Farsaci, Jo A. Tucker, James W. Hodge, David J. Liewehr, Seth M. Steinberg, Christopher R. Heery, Jeffrey Schlom	101
15	Brachyury, a Driver of the Epithelial–Mesenchymal Transition, Is Overexpressed in Human Lung Tumors: An Opportunity for Novel Interventions against Lung Cancer 2012 ·Clinical Cancer Research ·Mario Roselli, Romaine I. Fernando, Fiorella Guadagni, Antonella Spila, (unknown), Raffaele Palmirotta, Leopoldo Costarelli, Mary Litzinger, Duane H. Hamilton, (unknown), (unknown), (unknown), Jeffrey Schlom, Claudia Palena	102
16	A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer 2011 ·Clinical Cancer Research ·Mahsa Mohebtash, Kwong-Yok Tsang, Ravi A. Madan, Ngar‐Yee Huen, Diane J. Poole, Caroline Jochéms, Jacquin Jones, (unknown), Christopher R. Heery, Philip M. Arlen, Seth M. Steinberg, Mary Pazdur, Myrna Rauckhorst, Elizabeth C. Jones, William L. Dahut, Jeffrey Schlom, James L. Gulley	101
17	A Viral Vaccine Encoding Prostate-Specific Antigen Induces Antigen Spreading to a Common Set of Self-Proteins in Prostate Cancer Patients 2010 ·Clinical Cancer Research ·Nancy J. Nesslinger, Alvin V. Ng, Kwong-Yok Tsang, (unknown), Jeffrey Schlom, James L. Gulley, Brad H. Nelson	45
18	The Antitumor and Immunoadjuvant Effects of IFN-α in Combination with Recombinant Poxvirus Vaccines 2009 ·Clinical Cancer Research ·Kenneth W. Hance, Connie J. Rogers, David A. Zaharoff, Daniel Canter, Jeffrey Schlom, John W. Greiner	21
19	Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma 2008 ·Clinical Cancer Research ·James L. Gulley, Philip M. Arlen, Kwong-Yok Tsang, Junko Yokokawa, Claudia Palena, Diane J. Poole, Cinzia Remondo, Vittore Cereda, Jacquin Jones, Mary Pazdur, Jack P. Higgins, James W. Hodge, Seth M. Steinberg, Herbert L. Kotz, William L. Dahut, Jeffrey Schlom	176
20	Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy 2008 ·Clinical Cancer Research ·Ravi A. Madan, James L. Gulley, Jeffrey Schlom, Seth M. Steinberg, David J. Liewehr, William L. Dahut, Philip M. Arlen	119

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact